# Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.

> **NCT06662019** · PHASE1 · COMPLETED · sponsor: **NeoTrials Pty Ltd** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** N-IP-00001 inhalation solution
- **DRUG:** 0.9% NaCl isotonic saline solution

## Key facts

- **NCT ID:** NCT06662019
- **Lead sponsor:** NeoTrials Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-29
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662019, "Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06662019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*